Published in Biotech Business Week, May 19th, 2003
By analyzing phenotypic and genotypic assay results from more than 1000 HIV samples in ViroLogic's proprietary database, company researchers developed an improved, comprehensive scoring system for interpreting genotypic results. ViroLogic identified known and new mutations responsible for resistance to lopinavir and demonstrated that cross-resistance between lopinavir and amprenavir may be more...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.